COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE

Title:

COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE

Document Type and Number:

WIPO Patent Application WO/2017/059319

Kind Code:

A3

Abstract:

The present disclosure provides combination therapy of a bromodomain inhibitor and an immune modulator (e.g., an immune check point inhibitor). The combination of the bromodomain inhibitor and the immune modulator may be useful in treating or preventing cancer in a subject. In certain embodiments, the subject has an intact immune system. The combination of the bromodomain inhibitor and the immune modulator is expected to be synergistic.

More Like This:

JP2008514655	Carbonyl compounds used as inhibitors of coagulation factor Xa
WO/1995/032715	NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS
WO/1996/023506	USE OF 5'SUBSTITUTED NUCLEOSIDES TO PROVIDE RESISTANCE IN CYTOSTATIC TREATMENT AND MEDICAMENTS CONTAINING SAID NUCLEOSIDES

Inventors:

BRADNER JAMES E (US)
HOGG SIMON JOHN (AU)
JOHNSTON RICKY WAYNE (AU)
SHORTT JAKE (AU)

Application Number:

PCT/US2016/054924

Publication Date:

October 12, 2017

Filing Date:

September 30, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

DANA FARBER CANCER INST INC (US)
PETER MACCALLUM CANCER INST (AU)

International Classes:

A61K45/00; A61K31/437; A61K31/495; A61K31/519; A61K31/551; A61K45/06; A61P35/00

Domestic Patent References:

WO2015054642A2	2015-04-16
WO2014144721A2	2014-09-18
WO2015018522A1	2015-02-12
WO2012075456A1	2012-06-07
WO2015018521A1	2015-02-12
WO2014128111A1	2014-08-28
WO2014128070A1	2014-08-28
WO2011054553A1	2011-05-12

Other References:

A MOROS ET AL: "Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma", LEUKEMIA., 18 March 2014 (2014-03-18), US, XP055234731, ISSN: 0887-6924, DOI: 10.1038/leu.2014.106
DHONG HYUN LEE ET AL: "Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma", INTERNATIONAL JOURNAL OF CANCER, vol. 136, no. 9, 30 October 2014 (2014-10-30), US, pages 2055 - 2064, XP055365512, ISSN: 0020-7136, DOI: 10.1002/ijc.29269

Attorney, Agent or Firm:

ABELLEIRA, Susan, M. et al. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: SCAPHOPETALONE ANALOGS AND THEIR USES

Next Patent: LEASH WITH COLLAPSIBLE POCKETS